BNTX241220C125000
- 2.50
- -0.98-28.16%
BioNTech Newsroom
BioNTech SE (NASDAQ:BNTX) Surges 4.6%; Private Equity Firms Who Own 43% Shares Profited Along With Institutions
CCORF Initiates BioNTech(BNTX.US) With Buy Rating, Announces Target Price $171.44
Express News | Form 144 | BioNTech(BNTX.US) 10% Stockholder Proposes to Sell 5.26 Million in Common Stocks
European Equities Traded in the US as American Depositary Edge Higher in Wednesday Trading
BioNTech Price Target Raised to $171.44/Share From $171.00 by Canaccord Genuity
BioNTech Is Maintained at Buy by Canaccord Genuity
Deutsche Bank Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $150
A Quick Look at Today's Ratings for BioNTech(BNTX.US), With a Forecast Between $122 to $171.44
BioNTech SE (BNTX) Gets a Buy From Deutsche Bank
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
Promising Potential of BioNTech's BNT327 in Treating Triple-Negative Breast Cancer Drives Buy Rating
JP Morgan Maintains Neutral on BioNTech, Lowers Price Target to $122
BioNTech Analyst Ratings
Jefferies Reaffirms Their Buy Rating on BioNTech SE (BNTX)
Analysts Conflicted on These Healthcare Names: Aveanna Healthcare Holdings (AVAH) and BioNTech SE (BNTX)
J.P. Morgan Maintains BioNTech(BNTX.US) With Hold Rating
TD Cowen Maintains BioNTech(BNTX.US) With Hold Rating, Maintains Target Price $122
BioNTech SE (BNTX) Receives a Hold From TD Cowen
J.P. Morgan Releases a Hold Rating on BioNTech SE (BNTX)
Express News | BioNTech SE : JP Morgan Cuts Target Price to $122 From $124